Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01059474 · ClinicalTrials.gov registry record · Phase 1
Transdermal Absorption of Dimercaptopropane-1-Sulfonate (DMPS) and Effect on Urinary Mercury Excretion
A Phase 1 study, sponsored by Banner Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01059474 is a Phase 1 study that has completed, run by Banner Health. The registered enrollment target is 9 participants.
The verdict
NCT01059474, a Phase 1 study, has completed, sponsored by Banner Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
DMPS is a metal chelator which is approved for use in Europe. While not an FDA-approved drug in the US, it is easily obtained and administered by alternative health practitioners to their patients. A formulation called 'TD DMPS' (transdermal DMPS) is in use, despite the fact there is no published literature to support that the agent is absorbed transdermally. The investigators hypothesis is that DMPS is not absorbed through the skin. The investigators plan to apply TD DMPS to healthy volunteers and then test serum for presence of DMPS. In addition the investigators will measure urinary mercury concentrations pre and post DMPS application.
Interventions
- DRUG transdermal DMPS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01059474
The ClinicalTrials.gov registry entry for NCT01059474 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Banner Health, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which transdermal DMPS is the first listed.
NCT01059474 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01059474 about?
NCT01059474 is a clinical study titled "Transdermal Absorption of Dimercaptopropane-1-Sulfonate (DMPS) and Effect on Urinary Mercury Excretion". DMPS is a metal chelator which is approved for use in Europe. While not an FDA-approved drug in the US, it is easily obtained and administered by alternative health practitioners to their patients. A formulation called 'TD DMPS' (transdermal DMPS) is in use, despite the fact there is no published li...
What is the current status of trial NCT01059474?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2010-04. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01059474?
The interventions under investigation include: transdermal DMPS (DRUG).
Who is sponsoring clinical trial NCT01059474?
This trial is sponsored by Banner Health, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.